Publications:

T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity.

Cancers

Sailer, Nadja N; Fetzer, Ina I; Salvermoser, Melanie M; Braun, Monika M; Brechtefeld, Doris D; Krendl, Christian C; Geiger, Christiane C; Mutze, Kathrin K; Noessner, Elfriede E; Schendel, Dolores J DJ; Bürdek, Maja M; Wilde, Susanne S; Sommermeyer, Daniel D

Publication Date: 2022-04-14

Variant appearance in text: APC: P1268L

PubMed Link: 35454906

Variant Present in the following documents:

• Main text
• cancers-14-01998.pdf

View BVdb publication page